Intravenous administration of an oxygen-enabled fluid
US-9649335-B1 · May 16, 2017 · US
Oxygen-enabled composition
US9980909B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9980909-B2 |
| Application number | US-201715493688-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 21, 2017 |
| Priority date | Mar 30, 2016 |
| Publication date | May 29, 2018 |
| Grant date | May 29, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A composition of chlorine-free poly-oxygenated aluminum hydroxide that comprises a clathrate containing oxygen gas molecules. In one embodiment, the poly-oxygenated aluminum hydroxide has particles having a diameter of 212 microns or less. The composition may be homogeneous.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition, comprising: a quantity of poly-oxygenated aluminum hydroxide comprising a clathrate containing oxygen gas molecules that is chlorine-free, wherein the poly-oxygenated aluminum hydroxide comprises particles each having a diameter of less than or equal to 212 μm. 2. The composition as specified in claim 1 , wherein the poly-oxygenated aluminum hydroxide is homogeneous. 3. The composition as specified in claim 2 , wherein the particles each have a diameter in the range of 107-212 um. 4. The composition as specified in claim 2 , wherein the particles each have a diameter in the range of 46-106 um. 5. The composition as specified in claim 2 , wherein the particles each have a diameter in the range of 26-45 um. 6. A quantity of poly-oxygenated aluminum hydroxide comprising a clathrate containing oxygen gas molecules that is chlorine-free, wherein the composition is not a desiccant. 7. A quantity of poly-oxygenated aluminum hydroxide comprising a clathrate containing oxygen gas molecules that is chlorine-free, wherein the poly-oxygenated aluminum hydroxide is configured to be intravenously delivered to a mammal. 8. A quantity of poly-oxygenated aluminum hydroxide comprising a clathrate containing oxygen gas molecules that is chlorine-free, wherein the poly-oxygenated aluminum hydroxide is configured to not create an immune response of a mammal. 9. The composition as specified in claim 8 wherein poly-oxygenated aluminum hydroxide is configured to be therapeutically effective in treating a condition of the mammal. 10. A quantity of poly-oxygenated aluminum hydroxide comprising a clathrate containing oxygen gas molecules that is chlorine-free, wherein the poly-oxygenated aluminum hydroxide is configured to deposit deep into a lung and perfuse out the lining of the lung. 11. A quantity of poly-oxygenated aluminum hydroxide comprising a clathrate containing oxygen gas molecules that is chlorine-free, wherein the poly-oxygenated aluminum hydroxide is configured to penetrate through epidermis and dermis layers of skin and reside in a subcutaneous layer of the skin. 12. A quantity of poly-oxygenated aluminum hydroxide comprising a clathrate containing oxygen gas molecules that is chlorine-free, wherein the poly-oxygenated aluminum hydroxide is configured to absorb through lining of an esophagus and a stomach. 13. A quantity of poly-oxygenated aluminum hydroxide comprising a clathrate containing oxygen gas molecules that is chlorine-free, wherein the poly-oxygenated aluminum hydroxide is configured to traverse a brood brain barrier (BBB) of a mammal. 14. A quantity of poly-oxygenated aluminum hydroxide comprising a clathrate containing oxygen gas molecules that is chlorine-free, wherein the poly-oxygenated aluminum hydroxide is configured to stay in a capillary, vein, or artery linings of a mammal circulatory system and not passively diffuse past a lining into surrounding tissue. 15. A composition, comprising: a quantity of poly-oxygenated aluminum hydroxide comprising a clathrate containing oxygen gas molecules that is chlorine-free, wherein the composition comprises particles each having a diameter of less than or equal to 212 μm; and wherein the quantity of poly-oxygenated aluminum hydroxide is homogeneous. 16. The composition of claim 15 , wherein the composition is made by a process that filters a quantity of a poly-oxygenated aluminum hydroxide.
Assignees
Inventors
Classifications
Inorganic compounds · CPC title
Aluminium oxide; Aluminium hydroxide; Aluminates · CPC title
Medicinal preparations containing inorganic active ingredients · CPC title
Oxides; Hydroxides · CPC title
Blood substitute; Oxygen transporting formulations; Plasma extender · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9980909B2 cover?
- A composition of chlorine-free poly-oxygenated aluminum hydroxide that comprises a clathrate containing oxygen gas molecules. In one embodiment, the poly-oxygenated aluminum hydroxide has particles having a diameter of 212 microns or less. The composition may be homogeneous.
- Who is the assignee on this patent?
- Univ Baylor
- What technology area does this patent fall under?
- Primary CPC classification A61K9/143. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).